EHA 2022 | Using MRD to better understand treatment responses in patients with CLL
Othman Al-Sawaf
• 11 Jun 2022
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, summarizes the importance of using measurable residual disease (MRD) to better understand and classify patient responses to therapy in chronic lymphocytic leukemia (CLL), and further highlights how MRD can be used to improve patient outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
